How GLP-1 Drugs Are Reshaping Obesity and Diabetes Treatment in Managed Care

Why Are GLP-1 Drugs Dominating Obesity and Diabetes Treatment?

GLP-1 receptor agonists — including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) — have fundamentally changed how clinicians approach obesity and type 2 diabetes. These drugs mimic the incretin hormone GLP-1, slowing gastric emptying, enhancing insulin secretion, and acting on brain appetite centers to reduce food intake. Clinical trials have demonstrated average weight reductions of 15–22% of body weight, far exceeding older pharmacotherapies.

Beyond weight loss, landmark trials such as the SELECT trial for semaglutide have shown meaningful reductions in major adverse cardiovascular events in patients with obesity, even without diabetes. The FDA has progressively expanded indications for these agents, and tirzepatide — a dual GIP/GLP-1 receptor agonist — has received approval for heart failure with preserved ejection fraction in patients with obesity. These expanding benefits are driving unprecedented demand across both endocrinology and primary care settings.

What Are the Managed Care Challenges of Rising GLP-1 Utilization?

The rapid uptake of GLP-1 drugs has created significant budgetary pressure on health plans, pharmacy benefit managers, and employers. According to discussions at the AMCP Annual 2026 meeting, GLP-1 medications now represent one of the largest pharmacy expenditure categories in the United States. With CDC estimates indicating that over 40% of US adults have obesity and more than 37 million have diabetes, the eligible patient population is enormous, and utilization shows no signs of plateauing.

Managed care organizations are responding with tiered formulary placement, prior authorization requirements, and step therapy protocols. Some plans are negotiating outcomes-based contracts with manufacturers, tying reimbursement to real-world weight loss or glycemic control thresholds. There is also growing debate about coverage parity — many insurers still treat obesity medications differently from diabetes medications, despite mounting evidence that sustained pharmacotherapy for obesity reduces downstream cardiovascular events, joint replacements, and hospitalizations.

What Does the Future Hold for GLP-1 Therapy?

The GLP-1 pipeline continues to expand rapidly. Oral semaglutide at higher doses has shown weight loss approaching that of injectable formulations, potentially removing a key barrier for patients who are reluctant to use injections. Meanwhile, experimental triple agonists targeting GLP-1, GIP, and glucagon receptors simultaneously are in late-stage clinical trials, with early data suggesting even greater weight reduction and metabolic improvement.

Researchers are also investigating GLP-1 drugs for conditions beyond obesity and diabetes. Studies are underway exploring their potential in metabolic dysfunction-associated steatohepatitis (MASH), chronic kidney disease, and even neurodegenerative disorders such as Alzheimer's disease. If these indications are validated, the already massive GLP-1 market could expand further, intensifying the need for thoughtful managed care policies that balance access with affordability.